Browse Studies — Arctuva

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Serum Phosphate Lowering Effect of Fixed Dose AP306 in Participants With Hyperphosphatemia Receiving Maintenance Hemodialysis

This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving mainten…

HyperphosphatemiaChronic Kidney Disease Requiring Chronic DialysisEnd Stage Renal Disease on Dialysis

Estimated

~$10 – $8,750

R1 TherapeuticsNCT06712654

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of childre…

Coronavirus Infection (COVID-19)Pulmonary Arterial HypertensionUrinary Tract Infections in Children+22 more

Estimated

~$10 – $750

Duke UniversityNCT04278404

Phase 3

A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main question…

HyperphosphatemiaChronic Kidney Disease, Receiving DialysisESRD (End-Stage Renal Disease)+1 more

Estimated

~$10 – $8,750

Alebund PharmaceuticalsNCT06933472